...
首页> 外文期刊>Internal medicine. >Azacitidine-Induced Pneumonitis in a Patient with Myelodysplastic Syndrome: First Case Report in Japan
【24h】

Azacitidine-Induced Pneumonitis in a Patient with Myelodysplastic Syndrome: First Case Report in Japan

机译:含氮氨基诱导的骨髓细胞增强症患者肺炎:日本的第一个案例报告

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

A 74-year-old Japanese man with myelodysplastic syndrome (MDS) received chemotherapy with azaci-tidine. From the second day after starting the administration, he complained of fever, cough and shortness of breath. Chest roentgenography and computed tomography showed consolidations and ground-glass opacities. His symptoms grew from worse to life-threatening. We diagnosed him with azacitidine-induced pneumonitis and began administering corticosteroids. Thereafter, his symptoms and radiographic abnormalities improved. Azacitidine is a hypomethylating agent that improves the survival of MDS patients. Although this drug is commonly well tolerated and rarely causes severe lung injury, it is important to consider the potentially serious adverse effects of azacitidine-induced pneumonitis.
机译:一个74岁的日本人,具有髓中异性增生综合征(MDS)接受了与Azaci-Tidine的化疗。 从开始行政后的第二天,他抱怨发烧,咳嗽和呼吸急促。 胸部射入和计算断层扫描显示整合和磨砂玻璃不透明度。 他的症状从危及生命造成的情况下变得更加糟糕。 我们诊断出含氮杂氨酸诱导的肺炎,并开始施用皮质类固醇。 此后,他的症状和射线照相异常改善了。 氮杂氨酸是一种低甲基化剂,其改善了MDS患者的存活。 虽然这种药物普遍耐受并且很少引起严重的肺损伤,但重要的是考虑含氮酰氨酸诱导的肺炎的潜在严重不利影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号